Literature DB >> 16109739

The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.

Yongxian Ma1, Pragati Katiyar, Laundette P Jones, Saijun Fan, Yiyu Zhang, Priscilla A Furth, Eliot M Rosen.   

Abstract

The progesterone receptor (PR) plays roles in normal mammary development and breast cancer formation, where it may exert both stimulatory and inhibitory actions. Previously, the breast cancer susceptibility gene product BRCA1 was found to interact with and inhibit the transcriptional activity of estrogen receptor-alpha. In this study, we found that exogenous wild-type BRCA1 inhibited the activity of the PR in transient transfection assays utilizing a mouse mammary tumor virus-Luc reporter. Wild-type BRCA1 inhibited the activity of endogenous PR in human breast cancer cells (T47D and MCF-7) and inhibited the activity of exogenous PR-A, PR-B, and [PR-A plus PR-B] isoforms. On the other hand, knockdown of endogenous BRCA1 using small interfering RNA enhanced the progesterone-stimulated activity of the PR by about 4-fold. We documented an in vivo association of the endogenous BRCA1 with PR isoforms A and B and a direct in vitro interaction between BRCA1 and PR, which was partially mapped. Whereas down-regulation of the coactivator p300 contributes to the BRCA1-mediated repression of estrogen receptor-alpha, this mechanism does not contribute to inhibition of PR activity, because exogenous p300 did not rescue the BRCA1 repression of PR activity. The BRCA1-PR interaction has functional consequences. Thus, we showed that BRCA1 inhibits the expression of various endogenous progesterone-responsive genes and inhibits progesterone-stimulated proliferation of T47D cells. Finally, exogenous progesterone caused an exaggerated proliferative response in the mammary glands of mice harboring a mammary-targeted conditional deletion of the full-length isoform of Brca1. These findings suggest that BRCA1 regulates the activity of progesterone, a major hormone of pregnancy that may also participate in mammary carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109739      PMCID: PMC4031608          DOI: 10.1210/me.2004-0488

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  61 in total

1.  BRCA1 inhibition of estrogen receptor signaling in transfected cells.

Authors:  S Fan; J Wang; R Yuan; Y Ma; Q Meng; M R Erdos; R G Pestell; F Yuan; K J Auborn; I D Goldberg; E M Rosen
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

2.  Protective effects of pregnancy and lactation against N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats.

Authors:  J Yang; K Yoshizawa; S Nandi; A Tsubura
Journal:  Carcinogenesis       Date:  1999-04       Impact factor: 4.944

3.  Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.

Authors:  J E Armes; L Trute; D White; M C Southey; F Hammet; A Tesoriero; A M Hutchins; G S Dite; M R McCredie; G G Giles; J L Hopper; D J Venter
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

4.  Cre-mediated gene deletion in the mammary gland.

Authors:  K U Wagner; R J Wall; L St-Onge; P Gruss; A Wynshaw-Boris; L Garrett; M Li; P A Furth; L Hennighausen
Journal:  Nucleic Acids Res       Date:  1997-11-01       Impact factor: 16.971

5.  Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.

Authors:  C A Wilson; L Ramos; M R Villaseñor; K H Anders; M F Press; K Clarke; B Karlan; J J Chen; R Scully; D Livingston; R H Zuch; M H Kanter; S Cohen; F J Calzone; D J Slamon
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

6.  Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay.

Authors:  S A Leonhardt; M Altmann; D P Edwards
Journal:  Mol Endocrinol       Date:  1998-12

7.  An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers.

Authors:  J Taylor; M Lymboura; P E Pace; R P A'hern; A J Desai; S Shousha; R C Coombes; S Ali
Journal:  Int J Cancer       Date:  1998-08-21       Impact factor: 7.396

8.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.

Authors:  X Xu; K U Wagner; D Larson; Z Weaver; C Li; T Ried; L Hennighausen; A Wynshaw-Boris; C X Deng
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

9.  Distinct steady-state nuclear receptor coregulator complexes exist in vivo.

Authors:  N J McKenna; Z Nawaz; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

10.  BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins.

Authors:  S Fan; J A Wang; R Q Yuan; Y X Ma; Q Meng; M R Erdos; L C Brody; I D Goldberg; E M Rosen
Journal:  Oncogene       Date:  1998-06-11       Impact factor: 9.867

View more
  49 in total

Review 1.  Challenges to defining a role for progesterone in breast cancer.

Authors:  Carol A Lange
Journal:  Steroids       Date:  2007-12-28       Impact factor: 2.668

Review 2.  Progesterone and breast cancer.

Authors:  Carol A Lange; Douglas Yee
Journal:  Womens Health (Lond)       Date:  2008-03

3.  BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage.

Authors:  Rahul D Ballal; Tapas Saha; Saijun Fan; Bassam R Haddad; Eliot M Rosen
Journal:  J Biol Chem       Date:  2009-09-21       Impact factor: 5.157

4.  Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.

Authors:  Yongxian Ma; York Tomita; Anju Preet; Robert Clarke; Erikah Englund; Scott Grindrod; Shyam Nathan; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2014-12

Review 5.  Progesterone regulation of stem and progenitor cells in normal and malignant breast.

Authors:  Sunshine Daddario Axlund; Carol A Sartorius
Journal:  Mol Cell Endocrinol       Date:  2011-09-16       Impact factor: 4.102

Review 6.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

7.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

8.  BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.

Authors:  Yongxian Ma; Saijun Fan; Changyan Hu; Qinghui Meng; Suzanne A Fuqua; Richard G Pestell; York A Tomita; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2009-11-03

9.  Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer.

Authors:  M Graeser; K Bosse; M Brosig; C Engel; R K Schmutzler
Journal:  Virchows Arch       Date:  2009-04-21       Impact factor: 4.064

Review 10.  BRCA1, hormone, and tissue-specific tumor suppression.

Authors:  Yanfen Hu
Journal:  Int J Biol Sci       Date:  2008-12-13       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.